140 related articles for article (PubMed ID: 8449602)
1. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc.
Henry JA; Hennessy C; Levett DL; Lennard TW; Westley BR; May FE
Int J Cancer; 1993 Mar; 53(5):774-80. PubMed ID: 8449602
[TBL] [Abstract][Full Text] [Related]
2. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
[TBL] [Abstract][Full Text] [Related]
3. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer.
Borg A; Baldetorp B; Fernö M; Olsson H; Sigurdsson H
Int J Cancer; 1992 Jul; 51(5):687-91. PubMed ID: 1612775
[TBL] [Abstract][Full Text] [Related]
4. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
Roux-Dosseto M; Romain S; Dussault N; Desideri C; Piana L; Bonnier P; Tubiana N; Martin PM
Eur J Cancer; 1992; 28A(10):1600-4. PubMed ID: 1356387
[TBL] [Abstract][Full Text] [Related]
5. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
6. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
7. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
Berns EM; Klijn JG; van Staveren IL; Portengen H; Noordegraaf E; Foekens JA
Eur J Cancer; 1992; 28(2-3):697-700. PubMed ID: 1350457
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
10. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
11. [The significance of c-erbB-2 and int-2 gene alterations and DNA ploidy pattern for aggressiveness of breast cancer].
Nagayama K; Watatani M; Maeda S; Imanishi Y; Kurooka K; Wada T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1993 Oct; 94(10):1144-52. PubMed ID: 7901748
[TBL] [Abstract][Full Text] [Related]
12. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
Machotka SV; Garrett CT; Schwartz AM; Callahan R
Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995
[TBL] [Abstract][Full Text] [Related]
14. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
Berns EM; Foekens JA; van Putten WL; van Staveren IL; Portengen H; de Koning WC; Klijn JG
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):13-9. PubMed ID: 1356012
[TBL] [Abstract][Full Text] [Related]
16. Analysis of oncogenes and tumor suppressor genes in human breast cancer.
Yamashita H; Kobayashi S; Iwase H; Itoh Y; Kuzushima T; Iwata H; Itoh K; Naito A; Yamashita T; Masaoka A
Jpn J Cancer Res; 1993 Aug; 84(8):871-8. PubMed ID: 8104920
[TBL] [Abstract][Full Text] [Related]
17. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.
Nagai MA; Pacheco MM; Brentani MM; Marques LA; Brentani RR; Ponder BA; Mulligan LM
Br J Cancer; 1994 Apr; 69(4):754-8. PubMed ID: 7908218
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
